{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:45:39Z","timestamp":1792431939114,"version":"4.5.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"\n Background<\/jats:title>\n Breast cancer is a common cause of cancer-related death worldwide. Chemotherapy plays an indispensable role in the conventional treatment of breast cancer, bringing some physical burdens and discomfort on cancer patients. Consequently, more and more patients turn to seeking the help of Complementary and Alternative Medicine (CAM), mainly traditional Chinese medicine (TCM). Xiaoyao san (XYS), a classical formula, has been shown to improve symptoms of breast cancer. An increasing number of researches suggest that compared to chemotherapy alone, Chinese herbal medicine combined with chemotherapy could increase effectiveness and reduce toxicity caused by chemotherapy. Emerging experimental research continuously demonstrated some of the components in XYS could stop breast cancer tumor cells from growing. However, the efficacy and safety of modified XYS combined with chemotherapy remain to be determined. Therefore, it is essential to evaluate the comparative effectiveness and safety of modified XYS combined with chemotherapy in-depth, thus providing clinicians and policymakers with evidence-based guidance and new treatment options.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To comprehensively evaluate the efficacy and safety of modified XYS in conjunction with chemotherapy in treating breast cancer by conducting a meta-analysis.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n 8 databases were systemically searched until April 3, 2022, including Web of Science PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang, Chinese Scientific Journals Database (VIP), and Chinese Biological Medical Database (CBM). Relevant randomized controlled trials (RCTs) comparing modified XYS in combination with chemotherapy versus chemotherapy alone were included. For the evaluation of methodological quality, Cochrane Collaboration was considered. Software Review Manager (version 5.4) was used for data analysis. Software STATA (version 15.0) was employed for sensitivity analysis and publication bias.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Altogether, 17 RCTs involving 1207 patients were investigated in the current review. The findings revealed that modified XYS combined with chemotherapy could lead to beneficial improvements compared to chemotherapy alone. More specifically, the combined therapy could enhance the short-term efficacy in the treatment of solid tumors (OR: 1.74; 95% CI 1.27 to\u00a02.39; P = 0.0006; I\n 2<\/jats:sup>\n = 0%); improve QOL (quality of life) (OR: 3.75; 95% CI 2.58 to 5.44; P &lt; 0.00001; I\n 2<\/jats:sup>\n = 0%); reduce clinical symptoms (OR: 3.69; 95% CI 1.43 to 9.49; P = 0.007; I\n 2<\/jats:sup>\n = 53%); ease depression (MD: -12.96; 95% CI -16.09 to -9.83; P &lt; 0.00001; I\n 2<\/jats:sup>\n = 0%); increase leukocytes (OR: 0.32; 95% CI 0.20 to 0.50; P &lt; 0.00001; I\n 2<\/jats:sup>\n = 0%) and platelets (OR: 0.37; 95% CI 0.20 to 0.67; P = 0.001; I\n 2<\/jats:sup>\n = 0%); reduce nausea and vomiting (OR: 0.26; 95% CI 0.15 to 0.44; P &lt; 0. 00001; I\n 2<\/jats:sup>\n = 0%); mitigate cardiotoxicity (OR: 0.16; 95% CI 0.07 to 0.36; P&lt;0.00001; I\n 2<\/jats:sup>\n = 0%); prolong survival time (OR: 2.19; 95% CI 1.03 to 4.66; P = 0.04; I\n 2<\/jats:sup>\n = 0%), compared to chemotherapy alone. Unfortunately, there was no statistically significant difference in damage to the liver and kidney (OR: 0.59; 95% CI 0.29 to 1.21; P = 0.15; I\n 2<\/jats:sup>\n = 0%).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The existing evidence suggests modified XYS combined with chemotherapy leads to beneficial improvements in the management of breast cancer, which may serve as a promising therapy for breast cancer in clinical practice. Given the limited number of high quality RCTs, more rigorous, scientific, double-blinded, large-scale, multi-center clinical trials are warranted further.<\/jats:p>\n <\/jats:sec>\n \n Systematic review registration<\/jats:title>\n \n https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:uri>\n , identifier CRD42022357860.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fonc.2023.1050337","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T01:30:46Z","timestamp":1679448646000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Modified xiaoyao san combined with chemotherapy for breast cancer: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"13","author":[{"given":"Junhua","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunlian","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dajun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"B1","article-title":"Analysis of zhang dezhong's skillful use of xiaoyao powder in treating breast cancer","volume":"23","author":"Chai","year":"2021","journal-title":"J Hubei Univ Tradit Chin Med"},{"key":"B2","first-page":"298","article-title":"Professor Wang keqiong's experience in treating breast cancer after radiotherapy with xiaoyao powder","volume":"40","author":"Zhu","year":"2021","journal-title":"J Tianjin Univ Tradit Chin Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s12013-014-0459-6","article-title":"Breast cancer: Epidemiology and etiology","volume":"72","author":"Tao","year":"2015","journal-title":"Cell Biochem Biophys"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S176070","article-title":"Epidemiological characteristics of and risk factors for breast cancer in the world","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-16-0858","article-title":"Global cancer in women: Burden and trends","volume":"26","author":"Torre","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B6","article-title":"Clinical epidemiological characteristics of multiple primary breast cancer: A retrospective study of 82 patients","volume":"26","author":"Shi","year":"2018","journal-title":"Modern Oncol"},{"key":"B7","first-page":"87","article-title":"Research progress on epidemiological trends and risk factors of female breast cancer","volume":"48","author":"Zhang","year":"2021","journal-title":"Res Cancer Prev Treat"},{"key":"B8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: A review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Nadia","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1017\/s1478951503030256","article-title":"Complementary and alternative medicine in breast cancer patients","volume":"1","author":"Nahleh","year":"2003","journal-title":"Palliat Support Care"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1142\/S0192415X20500780","article-title":"Positive role of Chinese herbal medicine in cancer immune regulation","volume":"48","author":"Wang","year":"2020","journal-title":"Am J Chin Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1142\/S0192415X18500507","article-title":"Application of traditional Chinese medicines as personalized therapy in human cancers","volume":"46","author":"Wang","year":"2018","journal-title":"Am J Chin Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1142\/S0192415X18500490","article-title":"Chinese Herbal medicine for advanced non-Small-Cell lung cancer: A systematic review and meta-analysis","volume":"46","author":"Zhang","year":"2018","journal-title":"Am J Chin Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1142\/S0192415X21500737","article-title":"Efficacy and safety of Chinese herbal medicine on treatment of breast cancer: A meta-analysis of randomized controlled trials","volume":"49","author":"Ho","year":"2021","journal-title":"Am J Chin Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160253","article-title":"A systematic review of randomized controlled trials on oral Chinese herbal medicine for prostate cancer","volume":"11","author":"Cao","year":"2016","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/1534735417722224","article-title":"Complementary Chinese herbal medicine therapy improves survival of patients with pancreatic cancer in Taiwan: A nationwide population-based cohort study","volume":"17","author":"Kuo","year":"2018","journal-title":"Integr Cancer Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9469276","article-title":"Chinese Herbal medicine as an adjunctive therapy for breast cancer: A systematic review and meta-analysis","volume":"2016","author":"Zhu","year":"2016","journal-title":"Evid Based Complement Alternat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3281968","article-title":"Chinese Herbal medicine as adjunctive therapy to chemotherapy for breast cancer: A systematic review and meta-analysis","volume":"2016","author":"Sun","year":"2016","journal-title":"Evid Based Complement Alternat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"Cochrane bias methods group; cochrane statistical methods group. the cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B21","first-page":"116","article-title":"Observation of the effect of xiaoyao San modified recipe in the treatment of depression syndrome of liver stagnation and spleen deficiency in patients with breast cancer after chemotherapy and analysis of the influence of SDS and HAMD scores","author":"Jin","year":"2020","journal-title":"Mother Baby World"},{"key":"B22","first-page":"66","article-title":"Observation of curative effect and toxic and side effects of jiawei xiaoyao powder combined with chemotherapy regimen in adjuvant treatment of breast cancer","volume":"26","author":"Lu","year":"2019","journal-title":"Capital Food Med"},{"key":"B23","article-title":"Clinical observation of modified xiaoyao powder combined with palliative chemotherapy in the treatment of patients with advanced breast cancer","volume":"23","author":"Li","year":"2017","journal-title":"Contemp Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.13935\/j.cnki.sjzx.160620","article-title":"Clinical study on the treatment of advanced breast cancer with soothing the liver and strengthening the spleen methods combined with chemotherapy","volume":"11","author":"Xu","year":"2016","journal-title":"World J Integr Med"},{"key":"B25","article-title":"Effects of xiaoyao powder on depression in postoperative chemotherapy patients with breast cancer","volume":"31","author":"Sun","year":"2016","journal-title":"Chin J Tradit Chin Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.15887\/j.cnki.13-1389\/r.2016.15.041","article-title":"Clinical observation of xiaoyao powder combined with capecitabine in the treatment of advanced triple-negative breast cancer","volume":"9","author":"Yang","year":"2016","journal-title":"J Clin Rational Drug Use"},{"key":"B27","article-title":"Observation of postoperative curative effect of jiawei xiaoyao powder combined with chemotherapy in the treatment of breast cancer","volume":"24","author":"Du","year":"2015","journal-title":"J Modern Integr Med"},{"key":"B28","article-title":"Clinical study of capecitabine maintenance therapy combined with xiaoyao powder in the treatment of advanced triple-negative breast cancer","volume":"23","author":"Wang","year":"2015","journal-title":"Int Med Health Rep"},{"key":"B29","article-title":"Observation on the effect of xiaoyao powder combined with sigiao capsules in the treatment of 21 cases of advanced breast cancer","volume":"39","author":"Yang","year":"2015","journal-title":"Guizhou Med"},{"key":"B30","unstructured":"ZhuJ\n Hubei University of Traditional Chinese MedicineThe clinical study of combining xiaoyao powder and xeloda on treating advanced triple negative breast cancer2014"},{"key":"B31","article-title":"Clinical analysis of the effect of xiaoyao powder on depression in patients with breast cancer after chemotherapy","author":"Sun","year":"2014"},{"key":"B32","first-page":"101+105","article-title":"Clinical study of heixiaoyao powder on the side effects of postoperative chemotherapy for breast cancer","author":"Sun","year":"2014","journal-title":"Sci Technol Inf"},{"key":"B33","unstructured":"WangYC\n Nanjing University of Chinese MedicineClinical study of soothing the liver and strengthening the spleen methods combined with GP chemotherapy in the treatment of advanced breast cancer2012"},{"key":"B34","article-title":"Efficacy of chemotherapy plus xiaoyao powder on breast cancer after modified radical mastectomy","volume":"25","author":"Huang","year":"2009","journal-title":"J Pract Med"},{"key":"B35","first-page":"38","article-title":"Clinical observation of jiawei xiaoyao powder in improving the toxic and side effects of postoperative chemotherapy for breast cancer","author":"Wen","year":"2006","journal-title":"J Hunan Univ Tradit Chin Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.13193\/j.archtcm.2003.06.166.huangzhf.106","article-title":"Analysis of 32 cases of breast cancer treated with xiaoyaosan and chemotherapy","author":"Huang","year":"2003","journal-title":"J Chin Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.13862\/j.cnki.cn43-1446\/r.2002.06.028","article-title":"Applying xiaoyaosan as main prescription to treating 32 cases of middle and late course of mammary cancer","author":"Zhang","year":"2002","journal-title":"Hunan Tradit Chin Med Herald"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(01)00486-7","article-title":"Global cancer statistics in the year 2000","volume":"2","author":"Parkin","year":"2001","journal-title":"Lancet Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2174\/138955713804484785","article-title":"Anti-breast cancer agents from Chinese herbal medicines","volume":"13","author":"You","year":"2013","journal-title":"Mini Rev Med Chem"},{"key":"B40","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12916-015-0439-8","article-title":"Progress in adjuvant chemotherapy for breast cancer: An overview","volume":"13","author":"Anampa","year":"2015","journal-title":"BMC Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2015.07.035","article-title":"Long term side effects of adjuvant chemotherapy in patients with early breast cancer","author":"Tao","year":"2015","journal-title":"Breast"},{"key":"B42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.13422\/j.cnki.syfjx.20220321","article-title":"Reversal of energy metabolism reprogramming of breast cancer MDA-MB-231 cells by danzhi xiaoyao powder containing serum","volume":"28","author":"Xu","year":"2022","journal-title":"Chin J Exp Formulas"},{"key":"B43","unstructured":"YangJH\n 10.27213\/d.cnki.glnzc.2020.000149Liaoning University of Traditional Chinese MedicineDanzhi xiaoyao powder regulates tumor-associated fibroblasts to inhibit the growth and metastasis of breast cancer and its molecular mechanism2020"},{"key":"B44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s2225-4110(16)30073-6","article-title":"The in vivo therapeutic effect of free wanderer powder ( xi\u0101o y\u00e1o s\u0103n xiaoyaosan) on mice with 4T1 cell induced breast cancer model","volume":"2","author":"Chen","year":"2012","journal-title":"J Tradit Complement Med"},{"key":"B45","unstructured":"LvP\n 10.26973\/d.cnki.gbjzu.2020.000445Beijing University of Chinese MedicineAnti-breast cancer mechanism of longbei xiaoyao powder regulating miR-145\/c-Myc\/TP53 signaling pathway2020"},{"key":"B46","article-title":"Research progress in antidepressant pharmacology of xiaoyao powder","volume":"37","author":"Zhou","year":"2022","journal-title":"Guangming TCM"},{"key":"B47","doi-asserted-by":"publisher","first-page":"15(1)","DOI":"10.4238\/gmr.15017500","article-title":"Estrogenic effects of flavonoid components in xiaoyao powder","volume":"11","author":"Chen","year":"2016","journal-title":"Genet Mol Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2020.11155","article-title":"Saikosaponin d inhibits autophagosome-lysosome fusion and induces autophagy-independent apoptosis in MDA-MB-231 breast cancer cells","volume":"22","author":"Fu","year":"2020","journal-title":"Mol Med Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3727\/096504018X15228018559434","article-title":"Kaempferol suppresses proliferation and induces cell cycle arrest, apoptosis, and DNA damage in breast cancer cells","volume":"27","author":"Zhu","year":"2019","journal-title":"Oncol Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3892\/or.2016.4804","article-title":"Ferulic acid exerts antitumor activity and inhibits metastasis in breast cancer cells by regulating epithelial to mesenchymal transition","volume":"36","author":"Zhang","year":"2016","journal-title":"Oncol Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2017.09.001","article-title":"Breast cancer: Multiple subtypes within a tumor","volume":"3","author":"Yeo","year":"2017","journal-title":"Trends Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1050337\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T01:31:02Z","timestamp":1679448662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1050337\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":51,"alternative-id":["10.3389\/fonc.2023.1050337"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1050337","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,22]]},"article-number":"1050337"}}